NCT02296125 2026-04-21
FLAURA
AstraZeneca
Phase 3 Completed
Clinical Trials
172 trialsNCT02152631 2026-02-06
JUNIPER
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
NCT00596648 2026-01-13
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Exelixis
Phase 1/2 Completed
NCT01708954 2025-11-28
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03137771 2025-11-25
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Active not recruiting
NCT00977470 2025-10-15
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT00983307 2025-04-30
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Thomas Jefferson University
Phase 2 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT00503971 2025-03-07
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Spanish Lung Cancer Group
Phase 1/2 Terminated
NCT00446225 2025-03-05
EURTAC
Spanish Lung Cancer Group
Phase 3 Completed
NCT02535338 2025-03-03
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02424617 2025-02-26
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
BerGenBio ASA
Phase 1/2 Completed
NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
NCT02495233 2024-11-27
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
Astellas Pharma Inc
Phase 1/2 Terminated
NCT01306045 2024-10-01
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02352948 2024-07-26
ARCTIC
AstraZeneca
Phase 3 Completed
NCT03076164 2024-04-02
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00750698 2023-07-06
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Syndax Pharmaceuticals
Phase 2 Terminated
NCT01104155 2023-06-22
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Eisai Inc.
Phase 2 Completed
NCT04179890 2023-05-25
UpSwinG
Boehringer Ingelheim
Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT01562028 2022-08-24
BELIEF
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT01652469 2022-08-24
EMPHASIS
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT00602030 2022-08-22
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT00553800 2022-07-12
NSCLC
Fox Chase Cancer Center
Phase 2 Completed
NCT00600015 2022-03-10
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT01454102 2021-10-12
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Bristol-Myers Squibb
Phase 1 Completed
NCT00871923 2021-09-16
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01211483 2021-06-16
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 1/2 Completed
NCT00452413 2021-05-13
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT01199068 2021-05-13
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase 1 Completed
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01244191 2021-04-06
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Daiichi Sankyo
Phase 3 Terminated
NCT00606502 2021-03-05
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT01302808 2021-01-20
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT00130728 2021-01-14
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 3 Completed
NCT01573702 2021-01-12
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00760929 2021-01-05
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Hoffmann-La Roche
Phase 2 Terminated
NCT00888511 2020-11-27
TARLAL
Odense University Hospital
Phase 2 Completed
NCT02318368 2020-10-22
FOCAL
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00950365 2020-09-16
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
Albert Einstein College of Medicine
Phase 2 Completed
NCT00547105 2020-08-21
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00278148 2020-07-20
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01857271 2020-07-08
EVENT
Albert Einstein College of Medicine
Phase 2 Terminated
NCT01101334 2020-06-16
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 2 Completed
NCT00436332 2020-04-02
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00445848 2020-03-05
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed